Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy

Lawrence Rice, Janet L. Nichol, Robert McMillan, Lorin K. Roskos, Margaret Bacile

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


We report a patient with cyclic thrombocytopenia and antiplatelet antibodies, a variant of chronic immune thrombocytopenic purpura (ITP), with a several year history of periodic fluctuation of the platelet count, megakaryocytic hyperplasia and high-titer anti-GPIb-specific antiplatelet antibodies. The patient was resistant to multiple forms of therapy but has responded to the thrombopoietic growth factor, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF). This case suggests that some patients with classic ITP may respond to thrombopoietic growth factors.

Original languageEnglish (US)
Pages (from-to)210-214
Number of pages5
JournalAmerican Journal of Hematology
Issue number3
StatePublished - 2001


  • Antiplatelet antibody
  • Cyclic thrombocytopenia
  • ITP
  • Thrombopoietin

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy'. Together they form a unique fingerprint.

Cite this